美国 · SEC FORM 4
Benitec Biopharma Inc.
BNTC · Nasdaq · CIK 0001808898 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
1 同一窗口内观察到的 Form 4 交易行
0 sales · 1 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2025-12-29 · Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC · $1.0M
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出无
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
BUCHI J KEVINDirector
○
● 买入▼ 卖出○ 其他
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-12-29 · Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC.
近期 Form 4 活动
14买入
0卖出
1其他 Form 4 交易行
4SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出0 sale line(s) · 仅供背景
其他1 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 2,039,457
- 上期报告
- 2,186,142
- 日均成交量
- 200,147
- 回补天数
- 10.2
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-12-29 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 77,387 | USD 13.44 | USD 1,040,081 | SEC 申报 ↗ |
| 2025-12-26 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 16,836 | USD 13.10 | USD 220,552 | SEC 申报 ↗ |
| 2025-12-23 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 50,000 | USD 12.85 | USD 642,500 | SEC 申报 ↗ |
| 2025-12-22 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 19,542 | USD 12.08 | USD 236,067 | SEC 申报 ↗ |
| 2025-12-19 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 16,384 | USD 11.48 | USD 188,088 | SEC 申报 ↗ |
| 2025-12-18 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 10,215 | USD 11.24 | USD 114,817 | SEC 申报 ↗ |
| 2025-11-07 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 1,481,481 | USD 13.50 | USD 19,999,994 | SEC 申报 ↗ |
| 2025-03-31 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 16,497 | USD 12.83 | USD 211,736 | SEC 申报 ↗ |
| 2025-03-26 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 900,000 | USD 13.00 | USD 11,700,000 | SEC 申报 ↗ |
| 2024-12-24 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 20,018 | USD 11.25 | USD 225,202 | SEC 申报 ↗ |
| 2024-12-23 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 27,502 | USD 10.98 | USD 301,972 | SEC 申报 ↗ |
| 2024-12-03 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 42,000 | USD 9.60 | USD 403,200 | SEC 申报 ↗ |
| 2024-11-20 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 27,436 | USD 10.22 | USD 280,396 | SEC 申报 ↗ |
| 2024-11-19 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 14,000 | USD 9.73 | USD 136,220 | SEC 申报 ↗ |
| 2023-08-11 | Boston Megan | 买入 (P) | Common Stock | 25,907 | USD — | USD — | SEC 申报 ↗ |
Form 4 申报证据
15 transaction lines in the latest 365-day window; 46 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-29 | BUCHI J KEVIN | 赠与 (G) | Common Stock | 51,813 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-29 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 77,387 | USD 13.44 | USD 1,040,081 | SEC 申报 ↗ |
| 2025-12-26 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 16,836 | USD 13.10 | USD 220,552 | SEC 申报 ↗ |
展开近期 Form 4 证据 (8 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-29 | BUCHI J KEVIN | 赠与 (G) | Common Stock | 51,813 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-29 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 77,387 | USD 13.44 | USD 1,040,081 | SEC 申报 ↗ |
| 2025-12-26 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 16,836 | USD 13.10 | USD 220,552 | SEC 申报 ↗ |
| 2025-12-23 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 50,000 | USD 12.85 | USD 642,500 | SEC 申报 ↗ |
| 2025-12-22 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 19,542 | USD 12.08 | USD 236,067 | SEC 申报 ↗ |
| 2025-12-19 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 16,384 | USD 11.48 | USD 188,088 | SEC 申报 ↗ |
| 2025-12-18 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 10,215 | USD 11.24 | USD 114,817 | SEC 申报 ↗ |
| 2025-11-07 | Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC | 买入 (P) | Common stock, par value $0.0001 per share | 1,481,481 | USD 13.50 | USD 19,999,994 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | BNTC |
| CIK | 0001808898 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 46 transaction lines from 2021-04-28 to 2026-06-29 38 P purchase lines · 0 S sale lines · 8 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.